Table 1 Characteristics of core strategy
Category | n = 1427 |
|---|---|
Status of antimicrobial use n (%) | 573 (40.2) |
Carbapenems use | 288 (20.2) |
3,4-Generation Cephalosporins, Quinolones | 149 (10.4) |
>14 inpatient days | |
Glycopeptides use | 136 (9.5) |
Isolation of pathogenic microorganisms n (%) | 854 (59.8) |
Blood culture - positive | 360 (25.2) |
MRSA | 334 (23.4) |
ESBLs | 73 (5.1) |
P. aeruginosa | 71 (5.0) |
Acinetobacter baumannii | 16 (1.1) |